FDA Grants Priority Review for AbbVie... - HFI Connect - Hep...

HFI Connect - Hepatitis

959 members1,215 posts

FDA Grants Priority Review for AbbVie's Hepatitis C Treatment

mwright profile image
0 Replies

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The NDA is for the treatment of adults with chronic genotype 4 (GT4) hepatitis C virus (HCV) infection. continue reading: bit.ly/1Hhn3Ow

Written by
mwright profile image
mwright
To view profiles and participate in discussions please or .
Read more about...